SGLT2 inhibitors, which have shown efficacy in improving patient outcomes in conditions including heart failure, diabetes mellitus, and diabetic nephropathy, saw a consistent increase in utilization by cardiologists, endocrinologists, and nephrologists from 2015 to 2021 [1]. The gene discussed is SLC5A2; the disease is diabetes mellitus.